# A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

> **NCT03899792** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Medullary Thyroid Cancer
- Infantile Myofibromatosis
- Infantile Fibrosarcoma
- Papillary Thyroid Cancer
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Selpercatinib

## Key facts

- **NCT ID:** NCT03899792
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-13
- **Primary completion:** 2024-11-08
- **Final completion:** 2029-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899792, "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03899792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*